A serial biotech startup team is back in business, armed with $40M and a focus on NASH
Bob Baltera’s last stint as a biotech CEO was brief. In less than a year at the helm of Laguna he and the company produced some interesting late-stage data and a troubling set of safety issues that scuttled their work on atrial fibrillation.
“We shut that down and gave about half of the money (which would have been about $15 million) back to the investors,” he tells me in an experienced tone that suggests some things in this business just don’t work out the way you want it.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.